Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease

International Journal of Impotence Research volume 14, pages 178–188 (2002)Cite this article

Abstract

The association of erectile dysfunction (ED) and cardiovascular disease is well-documented in the literature and both conditions share risk factors. Therefore, it is difficult to distinguish the effect of underlying disease and adverse effects of the drugs and/or interactions between ED drugs and drugs implemented for cardiovascular disease. The known interactions of systemic administered drugs for ED with drugs for cardiovascular disease are mainly pharmacodynamic. Thus, nitrates enhance the production of cyclic GMP and combined with phosphodiesterase type-5 inhibitors this can lead to severe hypotension. The same is the case for the treatment with phentolamine in patients treated with β-adrenoceptor antagonists. Due to increased partial thromboplastin time, the risk of bleeding is enhanced for intracavernous alprostadil injection in heparin-treated patients. Pharmacokinetic interactions of clinical importance have been described for ED drugs with other therapeutic groups such as sildenafil with the antifungal drug, ketoconazole, and apomorphine with the antiparkinson drug, entacapon. Although sildenafil and antihypertensive dihydropyridines like amlodipine are metabolized by the same cytochrome P450 enzyme, CYP3A4 in the liver, the combination of these drugs does not exhibit a synergistic blood pressure lowering action. Unfortunately documentation concerning drug interactions is often poor and occasional.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study J Urol 1994 151: 54–61

    CAS  PubMed  Google Scholar 

  2. Martin-Morales A et al. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study J Urol 2001 166: 569–574

    CAS  PubMed  Google Scholar 

  3. Johannes CB et al. Incidence of erectile dysfunction in men 40 to 69 y old: longitudinal results from the Massachusetts male aging study J Urol 2000 163: 460–463

    CAS  PubMed  Google Scholar 

  4. Gundle MJ et al. Psychosocial outcome after coronary artery surgery Am J Psychiatry 1980 137: 1591–1594

    CAS  PubMed  Google Scholar 

  5. Wabrek AJ, Burchell RC . Male sexual dysfunction associated with coronary heart disease Arch Sex Behav 1980 9: 69–75

    CAS  PubMed  Google Scholar 

  6. Chang M, Hahn RA, Teutsch SM, Hutwagner LC . Multiple risk factors and population attributable risk for ischemic heart disease mortality in the United States, 1971–1992 J Clin Epidemiol 2001 54: 634–644

    CAS  PubMed  Google Scholar 

  7. Virag R, Bouilly P, Frydman D . Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men Lancet 1985 1: 181–184

    CAS  PubMed  Google Scholar 

  8. Shabsigh R, Fishman IJ, Schum C, Dunn JK . Cigarette smoking and other vascular risk factors in vasculogenic impotence Urology 1991 38: 227–231

    CAS  PubMed  Google Scholar 

  9. Morley JE et al. Relationship of penile brachial pressure index to myocardial infarction and cerebrovascular accidents in older men Am J Med 1988 84: 445–448

    CAS  PubMed  Google Scholar 

  10. Jensen J et al. The prevalence and etiology of impotence in 101 male hypertensive outpatients Am J Hypertens 1999 12: 271–275

    CAS  PubMed  Google Scholar 

  11. Fattinger K et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine Br J Clin Pharmacol 2000 49: 158–167

    CAS  PubMed  PubMed Central  Google Scholar 

  12. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee J Hypertens 1999 17: 151–183

  13. McCarron DA . Diuretic therapy for mild hypertension: the ‘real’ cost of treatment Am J Cardiol 1984 53: 9A–11A

    CAS  PubMed  Google Scholar 

  14. MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party Br Med J (Clin Res Ed) 1985 291: 97–104

  15. Chang SW et al. The impact of diuretic therapy on reported sexual function Arch Intern Med 1991 151: 2402–2408

    CAS  PubMed  Google Scholar 

  16. Grimm RH Jr et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS) Hypertension 1997 29: 8–14

    CAS  PubMed  Google Scholar 

  17. Bulpitt CJ et al. The effects of anti-hypertensive drugs on sexual function in men and women: a report from the DHSS Hypertension Care Computing Project (DHCCP) J Hum Hypertens 1989 3: 53–56

    CAS  PubMed  Google Scholar 

  18. Prisant LM et al. Self reported sexual dysfunction in men and women treated with bisoprolol, hydrochlorothiazide, enalapril, amlodipine, placebo, or bisoprolol/hydrochlorothia-zide J Clin Hypertens (Greenwich) 1999 1: 22–26

    CAS  Google Scholar 

  19. Burchardt M et al. Hypertension is associated with severe erectile dysfunction J Urol 2000 164: 1188–1191

    CAS  PubMed  Google Scholar 

  20. Cohen JS . Adverse drug effects, compliance, and initial doses of antihypertensive drugs recommended by the Joint National Committee vs the Physicians' Desk Reference Arch Intern Med 2001 161: 880–885

    CAS  PubMed  Google Scholar 

  21. Andersson KE, Wagner G . Physiology of penile erection Physiol Rev 1995 75: 191–236

    CAS  PubMed  Google Scholar 

  22. Simonsen U et al. Adrenoceptor-mediated regulation of the contractility in horse penile resistance arteries J Vasc Res 1997 34: 90–102

    CAS  PubMed  Google Scholar 

  23. Becker AJ et al. Plasma levels of cavernous and systemic norepinephrine and epinephrine in men during different phases of penile erection J Urol 2000 164: 573–577

    CAS  PubMed  Google Scholar 

  24. Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension Lancet 1981 2: 539–543

  25. Croog SH et al. The effects of antihypertensive therapy on the quality of life New Engl J Med 1986 314: 1657–1664

    CAS  PubMed  Google Scholar 

  26. Broekman CP, Haensel SM, Van de Ven LL, Slob AK . Bisoprolol and hypertension: effects on sexual functioning in men J Sex Marital Ther 1992 18: 325–331

    CAS  PubMed  Google Scholar 

  27. Fletcher AE et al. The effects of verapamil and propranolol on quality of life in hypertension J Hum Hypertens 1989 3: 125–130

    CAS  PubMed  Google Scholar 

  28. Hong CY et al. Calcium antagonists stimulate sperm motility in ejaculated human semen Br J Clin Pharmacol 1985 19: 45–49

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Fogari R et al. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study Am J Hypertens 1998 11: 1244–1247

    CAS  PubMed  Google Scholar 

  30. Fogari R et al. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study Am J Hypertens 2001 14: 27–31

    CAS  PubMed  Google Scholar 

  31. Kaplan SA et al. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction Urology 1998 52: 739–743

    CAS  PubMed  Google Scholar 

  32. Marquer C, Bressolle F . Moxisylyte: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in impotence Fundam Clin Pharmacol 1998 12: 377–387

    CAS  PubMed  Google Scholar 

  33. Jaffe A et al. Erectile dysfunction in hypertensive subjects. Assessment of potential determinants Hypertension 1996 28: 859–862

    CAS  PubMed  Google Scholar 

  34. Azadzoi KM, Goldstein I . Erectile dysfunction due to atherosclerotic vascular disease: the development of an animal model J Urol 1992 147: 1675–1681

    CAS  PubMed  Google Scholar 

  35. Ari G, Vardi Y, Finberg JP . Nitric oxide and penile erection in streptozotocin-diabetic rats Clin Sci (Colch) 1999 96: 365–371

    CAS  Google Scholar 

  36. Martinez C, Simonsen U . Decreased erectile function in renal hypertensive rats Pharmacol Toxicol 2001 89: 122

    Google Scholar 

  37. Saenz dT I et al. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence New Engl J Med 1989 320: 1025–1030

    Google Scholar 

  38. Garban H et al. Effect of aging on nitric oxide-mediated penile erection in rats Am J Physiol 1995 268: H467–H475

    CAS  PubMed  Google Scholar 

  39. Azadzoi KM et al. Relationship between cavernosal ischemia and corporal veno-occlusive dysfunction in an animal model J Urol 1997 157: 1011–1017

    CAS  PubMed  Google Scholar 

  40. Okabe H et al. The penis is not protected—in hypertension there are vascular changes in the penis which are similar to those in other vascular beds Int J Impot Res 1999 11: 133–140

    CAS  PubMed  Google Scholar 

  41. Toblli JE et al. Morphological changes in cavernous tissue in spontaneously hypertensive rats Am J Hypertens 2000 13: 686–692

    CAS  PubMed  Google Scholar 

  42. Hale TM, Okabe H, Heaton JP, Adams MA . Antihypertensive drugs induce structural remodeling of the penile vasculature J Urol 2001 166: 739–745

    CAS  PubMed  Google Scholar 

  43. Davies MK, Gibbs CR, Lip GY . ABC of heart failure. Management: diuretics, ACE inhibitors, and nitrates Br Med J 2000 320: 428–431

    CAS  Google Scholar 

  44. Packer M et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group New Engl J Med 1996 334: 1349–1355

    CAS  PubMed  Google Scholar 

  45. Pitt B et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators New Engl J Med 1999 341: 709–717

    CAS  PubMed  Google Scholar 

  46. Squire IB, Barnett DB . The rational use of beta-adrenoceptor blockers in the treatment of heart failure. The changing face of an old therapy Br J Clin Pharmacol 2000 49: 1–9

    CAS  PubMed  PubMed Central  Google Scholar 

  47. Cohn JN et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure New Engl J Med 1991 325: 303–310

    CAS  PubMed  Google Scholar 

  48. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group New Engl J Med 1997 336: 525–533

  49. Gupta S et al. A possible mechanism for alteration of human erectile function by digoxin: inhibition of corpus cavernosum sodium/potassium adenosine triphosphatase activity J Urol 1998 159: 1529–1536

    CAS  PubMed  Google Scholar 

  50. Prieto D, Simonsen U, Hernandez M, Garcia-Sacristan A . Contribution of K+ channels and ouabain-sensitive mechanisms to the endothelium-dependent relaxations of horse penile small arteries Br J Pharmacol 1998 123: 1609–1620

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Gupta S et al. Possible role of Na(+)-K(+)-ATPase in the regulation of human corpus cavernosum smooth muscle contractility by nitric oxide Br J Pharmacol 1995 116: 2201–2206

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Neri A et al. The effect of long-term administration of digoxin on plasma androgens and sexual dysfunction J Sex Marital Ther 1987 13: 58–63

    CAS  PubMed  Google Scholar 

  53. Frick MH et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease New Engl J Med 1987 317: 1237–1245

    CAS  PubMed  Google Scholar 

  54. Staels B et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism Circulation 1998 98: 2088–2093

    CAS  PubMed  Google Scholar 

  55. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994 344: 1383–1389

  56. Shepherd J et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group New Engl J Med 1995 333: 1301–1307

    CAS  PubMed  Google Scholar 

  57. Wei M et al. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction Am J Epidemiol 1994 140: 930–937

    CAS  PubMed  Google Scholar 

  58. Schneider J, Kaffarnik H . Impotence in patients treated with clofibrate Atherosclerosis 1975 21: 455–457

    CAS  PubMed  Google Scholar 

  59. Bain SC, Lemon M, Jones AF . Gemfibrozil-induced impotence Lancet 1990 336: 1389

    CAS  PubMed  Google Scholar 

  60. Bruckert E, Giral P, Heshmati HM, Turpin G . Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction J Clin Pharm Ther 1996 21: 89–94

    CAS  PubMed  Google Scholar 

  61. Kersten S, Wahli W . Peroxisome proliferator activated receptor agonists EXS 2000 89: 141–151

    CAS  PubMed  Google Scholar 

  62. Xu S et al. PPARalpha-dependent induction of liver microsomal esterification of estradiol and testosterone by a prototypical peroxisome proliferator Endocrinology 2001 142: 3554–3557

    CAS  PubMed  Google Scholar 

  63. Jackson G . Simvastatin and impotence Br Med J 1997 315: 31–32

    Google Scholar 

  64. Kostis JB, Rosen RC, Wilson AC . Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia J Clin Pharmacol 1994 34: 989–996

    CAS  PubMed  Google Scholar 

  65. Pedersen TR, Faergemann O . Simvastatin seems unlikely to cause impotence Br Med J 1999 318: 192

    CAS  Google Scholar 

  66. De Siati M et al. Priapism as a complication of heparin therapy Arch Ital Urol Androl 1999 71: 201–202

    CAS  PubMed  Google Scholar 

  67. Kulmala RV, Lehtonen TA, Tammela TL . Preservation of potency after treatment for priapism Scand J Urol Nephrol 1996 30: 313–316

    CAS  PubMed  Google Scholar 

  68. Helgason AR et al. Factors associated with waning sexual function among elderly men and prostate cancer patients J Urol 1997 158: 155–159

    CAS  PubMed  Google Scholar 

  69. Danjou P et al. Assessment of erectogenic properties of apomorphine and yohimbine in man Br J Clin Pharmacol 1988 26: 733–739

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Segraves RT, Bari M, Segraves K, Spirnak P . Effect of apomorphine on penile tumescence in men with psychogenic impotence J Urol 1991 145: 1174–1175

    CAS  PubMed  Google Scholar 

  71. Heaton JP et al. Recovery of erectile function by the oral administration of apomorphine Urology 1995 45: 200–206

    CAS  PubMed  Google Scholar 

  72. Heaton JP . Key issues from the clinical trials of apomorphine SL World J Urol 2001 19: 25–31

    CAS  PubMed  Google Scholar 

  73. Seeman P, Van Tol HH . Dopamine receptor pharmacology Trends Pharmacol Sci 1994 15: 264–270

    CAS  PubMed  Google Scholar 

  74. Fagan TC et al. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates Am J Cardiol 2001 88: 760–766

    CAS  PubMed  Google Scholar 

  75. Dula E et al. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group Urology 2000 56: 130–135

    CAS  PubMed  Google Scholar 

  76. Montastruc P, Damase-Michel C, Montastruc JL . Apomorphine potentiates vagal bradycardia Eur J Pharmacol 1989 166: 511–514

    CAS  PubMed  Google Scholar 

  77. Dlewati A, Watkins HO, Lokhandwala MF . Effects of SK&F 85174, a DA-1/DA-2 receptor agonist, on pre- and postganglionic sympathetic neurotransmission to the heart Eur J Pharmacol 1989 164: 197–203

    CAS  PubMed  Google Scholar 

  78. Mukai M et al. The inhibition of ganglionic transmission via presynaptic dopamine DA1 and postsynaptic DA2 receptor activation in the canine cardiac sympathetic ganglia J Pharmacol Exp Ther 1996 279: 822–829

    CAS  PubMed  Google Scholar 

  79. MicroMedex Incorporated. www.smi.dk 2000

  80. Argiolas A, Hedlund H . The pharmacology and clinical pharmacokinetics of apomorphine SL BJU Int 2001 88: (Suppl 3) 18–21

    CAS  PubMed  Google Scholar 

  81. Traish A et al. Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non-adrenergic mechanisms Int J Impot Res 1998 10: 215–223

    CAS  PubMed  Google Scholar 

  82. Goldstein I . Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction Int J Impot Res 2000 12: (Suppl 1) S75–S80

    CAS  PubMed  Google Scholar 

  83. Andersson KE, Stief C . Oral alpha adrenoceptor blockade as a treatment of erectile dysfunction World J Urol 2001 19: 9–13

    CAS  PubMed  Google Scholar 

  84. Seideman P et al. Prazosin first dose phenomenon during combined treatment with a beta- adrenoceptor blocker in hypertensive patients Br J Clin Pharmacol 1982 13: 865–870

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Tam SW, Worcel M, Wyllie M . Yohimbine: a clinical review Pharmacol Ther 2001 91: 215–243

    CAS  PubMed  Google Scholar 

  86. Winter JC, Rabin RA . Yohimbine as a serotonergic agent: evidence from receptor binding and drug discrimination J Pharmacol Exp Ther 1992 263: 682–689

    CAS  PubMed  Google Scholar 

  87. Ernst E, Pittler MH . Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials J Urol 1998 159: 433–436

    CAS  PubMed  Google Scholar 

  88. Tallentire D et al. Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197) Br J Pharmacol 1996 118: 63–72

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Mathes CW, Smith ER, Popa BR, Davidson JM . Effects of intrathecal and systemic administration of buspirone on genital reflexes and mating behavior in male rats Pharmacol Biochem Behav 1990 36: 63–68

    CAS  PubMed  Google Scholar 

  90. Mansoor GA . Herbs and alternative therapies in the hypertension clinic Am J Hypertens 2001 14: 971–975

    CAS  PubMed  Google Scholar 

  91. Lacomblez L et al. Effect of yohimbine on blood pressure in patients with depression and orthostatic hypotension induced by clomipramine Clin Pharmacol Ther 1989 45: 241–251

    CAS  PubMed  Google Scholar 

  92. Andersson KE . Pharmacology of penile erection Pharmacol Rev 2001 53: 417–450

    CAS  PubMed  Google Scholar 

  93. Langtry HD, Markham A . Sildenafil: a review of its use in erectile dysfunction Drugs 1999 57: 967–989

    CAS  PubMed  Google Scholar 

  94. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group New Engl J Med 1998 338: 1397–1404

    CAS  PubMed  Google Scholar 

  95. FDA. FDA Postmarketing safety of sildenafil citrate (Viagra) Food and Drug Administration Website: www.fda.gov 1998

  96. Feenstra J, Drie-Pierik RJ, Lacle CF, Stricker BH . Acute myocardial infarction associated with sildenafil Lancet 1998 352: 957–958

    CAS  PubMed  Google Scholar 

  97. Conti CR, Pepine CJ, Sweeney M . Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease Am J Cardiol 1999 83: 29C–34C

    CAS  PubMed  Google Scholar 

  98. Herrmann HC, Chang G, Klugherz BD, Mahoney PD . Hemodynamic effects of sildenafil in men with severe coronary artery disease New Engl J Med 2000 342: 1622–1626

    CAS  PubMed  Google Scholar 

  99. Przyklenk K, Kloner RA . Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis J Am Coll Cardiol 2001 37: 286–292

    CAS  PubMed  Google Scholar 

  100. Wallis RM, Corbin JD, Francis SH, Ellis P . Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro Am J Cardiol 1999 83: 3C–12C

    CAS  PubMed  Google Scholar 

  101. Webb DJ et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina J Am Coll Cardiol 2000 36: 25–31

    CAS  PubMed  Google Scholar 

  102. Ishikura F et al. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart Circulation 2000 102: 2516–2521

    CAS  PubMed  Google Scholar 

  103. Zusman RM, Prisant LM, Brown MJ . Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group J Hypertens 2000 18: 1865–1869

    CAS  PubMed  Google Scholar 

  104. Ballard SA et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes J Urol 1998 159: 2164–2171

    CAS  PubMed  Google Scholar 

  105. McAuley IW, Kim NN, Min K, Goldstein I, Traish AM . Intracavernosal sildenafil facilitates penile erection independent of the nitric oxide pathway J Androl 2001 22: 623–628

    CAS  PubMed  Google Scholar 

  106. Zhao L et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension Circulation 2001 104: 424–428

    CAS  PubMed  Google Scholar 

  107. Geelen P et al. Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current Circulation 2000 102: 275–277

    CAS  PubMed  Google Scholar 

  108. Medina P et al. Inhibition of neuroeffector transmission in human vas deferens by sildenafil Br J Pharmacol 2000 131: 871–874

    CAS  PubMed  PubMed Central  Google Scholar 

  109. Stief CG et al. Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue Urology 2000 55: 146–150

    CAS  PubMed  Google Scholar 

  110. Levesque PC et al. Anion and cation modulation of the guinea-pig ventricular action potential during beta-adrenoceptor stimulation Pflugers Arch 1993 424: 54–62

    CAS  PubMed  Google Scholar 

  111. Sugiyama A et al. Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs J Cardiovasc Pharmacol 2001 38: 940–946

    CAS  PubMed  Google Scholar 

  112. Warrington JS, Shader RI, von Moltke LL, Greenblatt DJ . In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions Drug Metab Dispos 2000 28: 392–397

    CAS  PubMed  Google Scholar 

  113. Dresser GK, Spence JD, Bailey DG . Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition Clin Pharmacokinet 2000 38: 41–57

    CAS  PubMed  Google Scholar 

  114. Merry C et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients AIDS 1999 13: F101–F107

    CAS  PubMed  Google Scholar 

  115. Zusman RM, Morales A, Glasser DB, Osterloh IH . Overall cardiovascular profile of sildenafil citrate Am J Cardiol 1999 83: 35C–44C

    CAS  PubMed  Google Scholar 

  116. Webb DJ, Freestone S, Allen MJ, Muirhead GJ . Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist Am J Cardiol 1999 83: 21C–28C

    CAS  PubMed  Google Scholar 

  117. Buvat J et al. Double-blind multicenter study comparing alprostadil alpha-cyclodextrin with moxisylyte chlorhydrate in patients with chronic erectile dysfunction J Urol 1998 159: 116–119

    CAS  PubMed  Google Scholar 

  118. Linet OI, Ogrinc FG . Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group New Engl J Med 1996 334: 873–877

    CAS  PubMed  Google Scholar 

  119. Porst H . The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience J Urol 1996 155: 802–815

    CAS  PubMed  Google Scholar 

  120. Porst H et al. Intracavernous Alprostadil Alfadex—an effective and well tolerated treatment for erectile dysfunction. Results of a long-term European study Int J Impot Res 1998 10: 225–231

    CAS  PubMed  Google Scholar 

  121. Limoge JP, Olins E, Henderson D, Donatucci CF . Minimally invasive therapies in the treatment of erectile dysfunction in anticoagulated cases: a study of satisfaction and safety J Urol 1996 155: 1276–1279

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology, University of Aarhus, Denmark

    U Simonsen

Authors
  1. U Simonsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U Simonsen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Simonsen, U. Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. Int J Impot Res 14, 178–188 (2002). https://doi.org/10.1038/sj.ijir.3900846

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3900846

Keywords

This article is cited by

Search

Advanced search

Quick links